DARE
Dare Bioscience, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.72
+1.11%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.9x
Market Cap
$13.97M
MomentumView details →
1D Return
+1.11%
YTD Return
−61.88%
RSI (14)
28.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.9x
Market Cap
$13.97M
RSI (14)
28.9
MomentumView details →
1D Return
+1.11%
YTD Return
−61.88%
SummaryUpdated Jun 1, 2026
Daré Bioscience, Inc. (NASDAQ:DARE) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in San Diego, California. The company focuses exclusively on developing and commercializing innovative healthcare products for women's health, addressing unmet medical needs across contraception, fertility, sexual health, and vaginal health. Since its IPO in April 2014, Daré has built a diverse pipeline of 12 development-stage candidates targeting nine different women's health indications, with its first FDA-approved product <b>XACIATO</b> launched commercially in 2024 through a partnership with Organon.
Similar companies
Latest newsMore news →
Daré Bioscience announced a new NIH funding award of approximately $908,000 to advance DARE-PTB2 for the prevention of preterm birth, with potential for an additional future-year grant of approximately $1.3 million.5d agoDaré Bioscience launched DARE to PLAY Sildenafil Cream, a 503B compounded version of its proprietary sildenafil cream formulation, while continuing to advance the product toward the FDA's 505(b)(2) regulatory pathway.10d ago